Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00113113
Status:
COMPLETED
Last Update Posted:
2013-01-23
First Post:
2005-06-03
Brief Title:
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Sponsor:
Astex Pharmaceuticals Inc
Organization:
Astex Pharmaceuticals Inc
Study Overview
Official Title:
Phase I Study of Rubitecan RFS 2000 in the Treatment of Cancer Patients With Organ Dysfunction
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cancer patients with liver or renal dysfunction will be treated with rubitecan capsules to define the maximum tolerated dose and the dose-limiting toxicity in this patient population and to perform pharmacokinetic studies of rubitecan in this patient population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RFS 2000-040 | None | None | None |
| SGI-RUB-040 | None | None | None |